ProtoKinetix Stock

ProtoKinetix CapEx/D&A

The CapEx to Depreciation Ratio of ProtoKinetix (PKTX) as of Aug 23, 2026 is 1.10. In the previous year, CapEx to Depreciation Ratio was 1.22 — a change of -10.39% (lower).

CapEx/D&A

1.10

YoY

-10.39%

Last updated:

CapEx to Depreciation Ratio of ProtoKinetix is 2026 1.10 . CapEx to Depreciation Ratio of ProtoKinetix was 2025 1.22 . It decreases by -10.39% lower compared to the previous year.

The ProtoKinetix CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2017
19.66 USD
Jan 1, 2018
11.82 USD
Jan 1, 2019
8.34 USD
Jan 1, 2020
23.39 USD
Jan 1, 2021
30.33 USD
Jan 1, 2022
2.26 USD
Jan 1, 2023
1.22 USD
Jan 1, 2024
1.10 USD
The ProtoKinetix CapEx/D&A history
YEARCapEx/D&AYoY
1.10-10.39%
1.22-45.74%
2.26-92.56%
30.33+29.65%
23.39+180.47%
8.34-29.43%
11.82-39.88%
19.66+97.98%
9.93-68.15%
31.17
Access this data via the Eulerpool API

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

CapEx to Depreciation Ratio of ProtoKinetix is 1.10 in 2026.

CapEx to Depreciation Ratio of ProtoKinetix changed from 1.22 to 1.10, representing a -10.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's ProtoKinetix with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

Cash Flow — ProtoKinetix

All Key Metrics — ProtoKinetix